Product Description
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FORUM
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Encenicline](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease|Schizophrenia|Cognitive Dysfunction
Phase 2: Alzheimer Disease|Smoking Cessation|Tobacco Use Disorder|Schizophrenia
Phase 1: Affective Disorders, Psychotic|Psychotic Disorders|Other|Schizophrenia|Healthy Volunteers|Kidney Diseases|Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EVP-6124-026 | P3 |
Terminated |
Alzheimer Disease |
2017-08-01 |
|
EVP-6124-025 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
|
EVP-6124-024 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
|
EVP-6124-027 | P2 |
Withdrawn |
Alzheimer Disease |
2016-10-01 |